Companies: 10,795·Total market cap: $144.5T

Nektar Therapeutics

Nektar Therapeutics

NKTRNASDAQHealthcare● Active

$55.79

$-1.54(-2.68%)

Market Cap$1.1B

P/E Ratio—

52W High$109

52W Low$7.99

Avg Volume1.0M

Open$57.20

Beta1.15

股票排行：Biotechnology·Healthcare·查看全部市值排行 →

Nektar Therapeutics（NKTR）股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · NKTR · 截至 Jun 8, 2026

关键指标

EPS (TTM)$-8.42Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)$55.6MFull revenue history

Dividend Yield不分红Dividend history

Shares Outstanding16.9MShares outstanding history

Next EarningsAug 6, 2026Est.Earnings history

探索 Nektar Therapeutics 数据

分析师预测$150 · Buy

股息不分红

营收$55.2M-43.89%

盈利EPS $-9.73-12.10%

财务快照

FY 2025Revenue$55.2M▼ 43.89% YoY

202320242025

FY 2025Net Income-$164.1M▼ 37.92% YoY

202320242025

FY 2025EPS$-9.73▼ 12.10% YoY

202320242025

TTM:Revenue: $55.6MNet Income: -$158.1MEPS: $-8.42View income statement →

分析师评级与目标价

Buy33 位分析师

Strong Buy

0

Buy

22

Hold

6

Sell

5

Strong Sell

0

12-Month Price Target

$80.00Low

$55.78Current

$149.60Avg Target上涨空间 168.17%

$192.00High

合计: 33 · 买入占比: 66.7%

根据过去 3 个月内 33 位华尔街分析师，NKTR 共识评级为 Buy，12 个月平均目标价 $149.60 （较现价 $55.78 上涨空间 168.17%）。

竞争对手与同行

#TickerCompanyPriceChangeMkt Cap

Nektar Therapeutics

$55.79-2.68%$1.1B #2

Amylyx Pharmaceuticals, Inc.

$12.90-3.75%$1.1B #3

Atai Beckley Inc.

$3.88-1.77%$1.4B #4

Enliven Therapeutics, Inc.

$34.15-1.21%$2.1B #5

$9.62-1.38%$1.3B #6

Inhibrx Biosciences, Inc.

$87.87+0.97%$1.3B

股票表现

1D-2.76%

1W-4.73%

1M-31.93%

3M-21.16%

YTD+31.84%

1Y+534.13%

5Y-77.51%

关于 Nektar Therapeutics

CEOHoward W. Robin

IPO DateMay 3, 1994

Employees61

CountryUS

Websitenektar.com

Nektar Therapeutics a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products includ…

Biotechnology HealthcareNASDAQUS

关于股票概览与关键数据

Nektar Therapeutics（NKTR）是 Biotechnology 行业的 Healthcare 类公司，于 May 3, 1994 在 NASDAQ 上市。截至最近交易日，NKTR 股价为 $55.78，市值约为 $1.1B。过去12个月累计回报 +534.13%，年初至今回报 +31.84%。

根据 33 位华尔街分析师，Nektar Therapeutics 股票共识评级为Buy，12个月平均目标价为 $149.60。2025 财年 Nektar Therapeutics 营收 $55.2M，净利润 -$164.1M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。

常见问题

截至最近一个交易日，Nektar Therapeutics（NKTR）股价为 $55.78，在 NASDAQ 上市，52周区间为 $7.99 – $109.00。

NKTR 最新股价NKTR quote todaylive ticker 实时行情

数据来源：Financial Modeling Prep最后更新：Jun 8, 2026本内容不构成投资建议